ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD).
+ 3 more risks
Worrying balance sheet with weak fundamentals.
Share Price & News
How has ProMIS Neurosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 23J's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 23J underperformed the German Biotechs industry which returned 8.4% over the past year.
Return vs Market: 23J underperformed the German Market which returned 13.7% over the past year.
Price Volatility Vs. Market
How volatile is ProMIS Neurosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is ProMIS Neurosciences undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether ProMIS Neurosciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as ProMIS Neurosciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of 23J’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through ProMIS Neurosciences regulatory filings.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
How is ProMIS Neurosciences forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 23J is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 23J is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 23J is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 23J is forecast to have no revenue next year.
High Growth Revenue: 23J is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 23J's Return on Equity is forecast to be high in 3 years time
How has ProMIS Neurosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 23J is currently unprofitable.
Growing Profit Margin: 23J is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 23J is unprofitable, and losses have increased over the past 5 years at a rate of -35.2% per year.
Accelerating Growth: Unable to compare 23J's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 23J is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 23J's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
How is ProMIS Neurosciences's financial position?
Financial Position Analysis
Short Term Liabilities: 23J has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: 23J has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: 23J is debt free.
Reducing Debt: 23J's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Inventory Level: 23J has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 23J's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 23J has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 23J has less than a year of cash runway if free cash flow continues to reduce at historical rates of -35% each year
What is ProMIS Neurosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 23J's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 23J's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 23J's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 23J's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 23J's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Elliot Goldstein (68yo)
Dr. Elliot Goldstein, M.D. has been the Chief Executive Officer and President of ProMIS Neurosciences Inc. (Alternate name -Amorfix Life Sciences Ltd.) since July 2015 respectively. Dr. Goldstein is a Co-F ...
CEO Compensation Analysis
Compensation vs Market: Elliot's total compensation ($USD666.33K) is above average for companies of similar size in the German market ($USD412.50K).
Compensation vs Earnings: Elliot's compensation has increased whilst the company is unprofitable.
|Executive Chairman||4.6yrs||CA$883.66k||2.83% CA$1.1m|
|Chief Financial Officer||2.9yrs||CA$80.42k||no data|
|Chief Development Officer||3.6yrs||CA$310.08k||0.10% CA$42.4k|
|Chief Medical Officer||1.4yrs||CA$1.20m||no data|
|Chief Physics Officer||4.4yrs||no data||no data|
|Head of Pharmacology/Toxicology||1.8yrs||no data||no data|
|Head of Manufacturing||1.8yrs||no data||no data|
Experienced Management: 23J's management team is considered experienced (3.3 years average tenure).
|Executive Chairman||4.6yrs||CA$883.66k||2.83% CA$1.1m|
|Independent Director||5.9yrs||no data||1.27% CA$514.0k|
|Independent Director||2.9yrs||no data||0.47% CA$188.5k|
|Member of Scientific Advisory Board||2.7yrs||no data||no data|
|Independent Director||3.3yrs||no data||no data|
|Independent Director||6.2yrs||no data||no data|
|Co-Chair of Scientific Advisory Board||0yrs||no data||no data|
|Independent Director||4.7yrs||no data||1.13% CA$454.8k|
Experienced Board: 23J's board of directors are considered experienced (4.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 23J insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.1%.
ProMIS Neurosciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: ProMIS Neurosciences, Inc.
- Ticker: 23J
- Exchange: DB
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$57.836m
- Listing Market Cap: CA$40.410m
- Shares outstanding: 275.41m
- Website: https://www.promisneurosciences.com
- ProMIS Neurosciences, Inc.
- 1920 Yonge Street
- Suite 200
- M4S 3E2
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PMN||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Oct 2005|
|ARFX.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Oct 2005|
|23J||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Oct 2005|
ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (AßO); and PMN330, a monoclonal antibody targeting toxic prionlike forms of AßO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 23:21|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.